A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
AstraZeneca
AstraZeneca
Eastern Cooperative Oncology Group
Ono Pharmaceutical Co. Ltd
Merck Sharp & Dohme LLC
Vejle Hospital
DualityBio Inc.
AstraZeneca
Arcus Biosciences, Inc.
AstraZeneca
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Jazz Pharmaceuticals
Eastern Cooperative Oncology Group
Seagen Inc.